BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, cerebrovascular, iron supplement, digestion, and other APIs and intermediates. In addition, the company offers veterinary drugs. BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.
Stock data | 2024 | Change |
---|---|---|
Price | $3.38 | N/A |
Market Cap | $1.43B | N/A |
Shares Outstanding | 422.47M | N/A |
Employees | 1.13K | N/A |